Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Kintara Therapeutics Inc (KTRA)

Kintara Therapeutics Inc (KTRA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 13,688
  • Shares Outstanding, K 1,616
  • Annual Sales, $ 0 K
  • Annual Income, $ -22,660 K
  • 60-Month Beta 1.19
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade KTRA with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate -2.80
  • Number of Estimates 1
  • High Estimate -2.80
  • Low Estimate -2.80
  • Prior Year -6.00
  • Growth Rate Est. (year over year) +53.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.50 +141.28%
on 11/23/22
10.40 -18.75%
on 12/01/22
+3.13 (+58.83%)
since 11/04/22
3-Month
3.50 +141.28%
on 11/23/22
10.40 -18.75%
on 12/01/22
+1.10 (+14.97%)
since 09/06/22
52-Week
3.50 +141.28%
on 11/23/22
42.00 -79.88%
on 04/11/22
-21.55 (-71.83%)
since 12/06/21

Most Recent Stories

More News
Wave of FDA Fast Track Designations Sparks Renewed Interest in Biotech Sector That's Heating Up

/PRNewswire/ -- USA News Group - A series of new Fast Track designations have been handed out by the United States Food and Drug Administration (FDA) this...

ONC.TO : 2.40 (-9.09%)
ONCY : 1.7900 (-7.25%)
RHHBY : 40.2700 (-1.35%)
ARAV : 1.4700 (-2.65%)
CRBU : 9.35 (+2.30%)
KTRA : 8.45 (-0.24%)
Wave of FDA Fast Track Designations Sparks Renewed Interest in Biotech Sector That’s Heating Up

FN Media Group Presents USA News Group News Commentary   Vancouver, BC –December 1, 2022 – USA News Group  –  A series of new Fast Track designations have been handed out by the United States...

ONCY : 1.7900 (-7.25%)
ONC.TO : 2.40 (-9.09%)
RHHBY : 40.2700 (-1.35%)
ARAV : 1.4700 (-2.65%)
CRBU : 9.35 (+2.30%)
KTRA : 8.45 (-0.24%)
Latest Set of FDA Fast Track Designations Causing Optimism in Biotech Sector

USA News Group – A series of new Fast Track designations have been handed out by the United States Food and Drug Administration (FDA) this week, causing a flurry of activity in the markets for the worthy...

ONCY : 1.7900 (-7.25%)
ONC.TO : 2.40 (-9.09%)
RHHBY : 40.2700 (-1.35%)
ARAV : 1.4700 (-2.65%)
CRBU : 9.35 (+2.30%)
KTRA : 8.45 (-0.24%)
Kintara Therapeutics Granted Fast Track Designation from FDA for REM-001 for Cutaneous Metastatic Breast Cancer

/PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid...

KTRA : 8.45 (-0.24%)
Kintara Therapeutics Presents Three Posters at the 2022 Society for Neuro-Oncology Annual Meeting

/PRNewswire/ -- Kintara Therapeutics, Inc.(Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid...

KTRA : 8.45 (-0.24%)
Kintara Announces One-for-Fifty Reverse Stock Split

/PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid...

KTRA : 8.45 (-0.24%)
Kintara Therapeutics Announces Fiscal 2023 First Quarter Financial Results and Provides Corporate Update

/PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid...

KTRA : 8.45 (-0.24%)
Kintara Therapeutics Pauses REM-001 Program to Conserve Funds to Support VAL-083 International Registrational Study

/PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid...

KTRA : 8.45 (-0.24%)
Kintara Therapeutics Announces Three Abstracts Have Been Accepted for the 2022 Society for Neuro-Oncology Annual Meeting

/PRNewswire/ -- Kintara Therapeutics, Inc.(Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid...

KTRA : 8.45 (-0.24%)
Kintara Therapeutics Enters Into Equity Purchase Agreement for Up to $20 Million with Lincoln Park Capital

/PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) (Kintara or the Company), a biopharmaceutical company focused on the development of new solid tumor...

KTRA : 8.45 (-0.24%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Kintara Therapeutics Inc. is a biopharmaceutical company. It is focused on the development of new solid tumor cancer therapies. The company's program includes VAL-083 for GBM and REM-001 for cutaneous metastatic breast cancer, which are in clinical stage. Kintara Therapeutics Inc. is based in San Diego,...

See More

Key Turning Points

3rd Resistance Point 9.72
2nd Resistance Point 9.21
1st Resistance Point 8.83
Last Price 8.45
1st Support Level 7.94
2nd Support Level 7.43
3rd Support Level 7.05

See More

52-Week High 42.00
Fibonacci 61.8% 27.29
Fibonacci 50% 22.75
Fibonacci 38.2% 18.21
Last Price 8.45
52-Week Low 3.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar